Search

Displaying results 4491 - 4500 of 9670 in total
  1. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  2. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    It is developed for the treatment of osteoporosis.

  3. Drug

    Nadifloxacin

    go.drugbank.com/drugs/DB12447
    Investigational

    Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.

  4. Drug

    Me-4(18F)DG

    go.drugbank.com/drugs/DB19207
    Investigational

    Me-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).

  5. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.

  6. Drug

    Pyrroloquinoline Quinone

    go.drugbank.com/drugs/DB03205
    Investigational

    A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]

  7. Drug

    Lucitanib

    go.drugbank.com/drugs/DB11845
    Investigational

    Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

  8. Drug

    Chlorproguanil

    go.drugbank.com/drugs/DB12314
    Investigational

    Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.

  9. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that...

  10. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and partially functional dystrophin protein.